ScreenerHero

RMTIRockwell Medical, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · rockwellmed.com
8.100USD+8.00%Mkt Cap: 32.65M $P/E: —

Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap32.65M $
Enterprise Value19.93M $
Revenue (TTM)69.39M $
Gross Profit11.70M $
Net Income (TTM)-5.31M $
Revenue/Share17.97 USD
Last Price8.100 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees157
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS7743743004
Valuation
P/E (Trailing)—
P/E (Forward)109.14
PEG4.43
EV/EBITDA-8.20
EV/Revenue0.29
P/S0.44
P/B0.84
EPS (TTM)-1.34
EPS (Forward)0.07
52W Range
4.88520% of range21.00
52W High21.00 USD
52W Low4.885 USD
Profitability
Gross Margin16.89%
Oper. Margin-5.97%
EBITDA Margin-3.50%
Profit Margin-7.67%
ROE-14.37%
ROA-9.30%
Growth
Revenue Growth10.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-659.00K $
CapEx (TTM)542.00K $
FCF Margin0.50%
FCF Yield1.07%
Net Debt-10.86M $
Net Debt/EBITDA4.47
Balance Sheet
Debt/Equity0.24
Current Ratio3.25
Quick Ratio2.96
Book Value/Sh9.085 USD
Cash/Share6.152 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJul 1, 2026
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)20.00 USD
Upside (mean)+146.9%
Target Range20.00 USD – 20.00 USD
# Analysts2
Ownership
Shares Out.4.03M
Float3.58M
Insiders14.80%
Institutions8.52%
Short Interest
Short Ratio2.5d
Short % Float2.56%
Short % Out.2.50%
Shares Short98.50K
Short (prev mo.)80.33K
Technical
SMA 506.571 (+23.3%)
SMA 2008.575 (-5.5%)
Beta1.62
S&P 52W Chg18.16%
Avg Vol (30d)29.38K
Avg Vol (10d)35.48K
Technical Indicators
RSI (14)67.2
MACD0.3188
MACD Signal0.2582
MACD Hist.+0.0606
BB Upper7.985 USD
BB Middle7.221 USD
BB Lower6.457 USD
BB Width21.15%
ATR (14)0.4809 USD
Vol Ratio (20d)0.95x